Corpus overview


MeSH Disease

Human Phenotype

Fever (9)

Anosmia (6)

Cough (4)

Pneumonia (3)

Myalgia (3)


    displaying 41 - 50 records in total 181
    records per page


    Authors: Jose E Gonzalez; Pampi Majumder; Kingshuk Bhattacharjee; Qianting Yang; Haiyan Wang; Xin Wang; Xiaoju Liu; Juanjuan Zhao; Xuejiao Liao; Yang Liu; Ido Amit; Lei Liu; Shuye Zhang; Zheng Zhang; Christiane Schueler; Saskia Stenzel; Elisabeth Braun; Johanna Weiss; Daniel Sauter; Jan Muench; Steffen Stenger; Kei Sato; Alexander Kleger; Christine Goffinet; Konstantin Maria Johannes Sparrer; Frank Kirchhoff; Austin D. Swafford; Karsten Zengler; Susan Cheng; Michael Inouye; Teemu Niiranen; Mohit Jain; Veikko Salomaa; Jeffrey D. Esko; Nathan E Lewis; Rob Knight

    doi:10.1101/2020.08.15.20175653 Date: 2020-08-17 Source: medRxiv

    Data posted in the COVID 19 tracking website for RT-PCR (PCR) results and hospital admissions are used to estimate the prevalence SERO of the SARS-CoV-2 pandemic in the United States (1). Hospital admissions mitigate positive sampling bias in PCR tests due to their initially limited test numbers and application as a diagnostic, instead of a surveying tool. As of July 31, the United States' cumulative recovered population is estimated at 47% or 155 million. The remaining susceptible population is 53%, or 47% excepting the 6% infectious population. The estimated mortality rate of the cumulative recovered population is 0.09% death per case. New York and Massachusetts show SARS-CoV-2 prevalence SERO of 87% and 55%, respectively. Likewise, each state exhibits relatively low current positive PCR results at 1 % and 1.7%. Also, these states show about twice the mortality rate of the nation. Florida, California, and Texas showed recovered population percent around 40%, higher current PCR positive test results ranging from 7% to 13%. A higher recovered population mitigates the current positive value attainable by limiting the infectivity rate Re. This approach provides an alternate source of information on the pandemic's full time course since the serological testing SERO only views a narrow time slice of its history due to the transient nature of the antibody SERO response and its graduated expression dependency on the severity of the disease. The deficiency of serological testing SERO to estimate the recovered population is made even more acute due to the large proportion of asymptomatic TRANS and sub-clinical cases in the COVID-19 pandemic

    Detection, prevalence SERO, and duration of humoral responses to SARS-CoV-2 under conditions of limited population exposure.

    Authors: Tyler J Ripperger; Jennifer L Uhrlaub; Makiko Watanabe; Rachel Wong; Yvonne Castaneda; Hannah A Pizzato; Mallory R Thompson; Christine Bradshaw; Craig C Weinkauf; Christian Bime; Heidi L Erickson; Kenneth Knox; Billie Bixby; Sairam Parthasarathy; Sachin Chaudhary; Bhupinder Natt; Elaine Cristan; Tammer El Aini; Franz Rischard; Janet Campion; Madhav Chopra; Michael Insel; Afshin Sam; James L Knepler; Andrew P Capaldi; Catherine M Spier; Michael D Dake; Taylor Edwards; Matthew E Kaplan; Serena Jain Scott; Cameron Hypes; Jarrod Mosier; David T Harris; Bonnie J Lafleur; Ryan Sprissler; Janko Nikolich-Zugich; Deepta Bhattacharya

    doi:10.1101/2020.08.14.20174490 Date: 2020-08-16 Source: medRxiv

    We conducted an extensive serological study to quantify population-level exposure and define correlates of immunity against SARS-CoV-2. We found that relative to mild COVID-19 cases, individuals with severe disease exhibited elevated authentic virus-neutralizing titers and antibody SERO levels against nucleocapsid (N) and the receptor binding domain (RBD) and the S2 region of spike protein. Unlike disease severity, age TRANS and sex played lesser roles in serological responses. All cases, including asymptomatic TRANS individuals, seroconverted by 2 weeks post-PCR confirmation. RBD- and S2-specific and neutralizing antibody SERO titers remained elevated and stable for at least 2-3 months post-onset, whereas those against N were more variable with rapid declines MESHD in many samples. Testing of 5882 self-recruited members of the local community demonstrated that 1.24% of individuals showed antibody SERO reactivity to RBD. However, 18% (13/73) of these putative seropositive samples failed to neutralize authentic SARS-CoV-2 virus. Each of the neutralizing, but only 1 of the non-neutralizing samples, also displayed potent reactivity to S2. Thus, inclusion of multiple independent assays markedly improved the accuracy of antibody tests SERO in low seroprevalence SERO communities and revealed differences in antibody SERO kinetics depending on the viral antigen. In contrast to other reports, we conclude that immunity is durable for at least several months after SARS-CoV-2 infection MESHD.

    Antibody SERO prevalence SERO for SARS-CoV-2 in England following first peak of the pandemic: REACT2 study in 100,000 adults TRANS

    Authors: Helen Ward; Christina J Atchison; Matthew Whitaker; Kylie E. C. Ainslie; Joshua Elliott; Lucy C Okell; Rozlyn Redd; Deborah Ashby; Christl A. Donnelly; Wendy Barclay; Ara Darzi; Graham Cooke; Steven Riley; Paul Elliott; Rachel Vreeman; Joseph Masci; Nick A Maskell; Shaney Barratt

    doi:10.1101/2020.08.12.20173690 Date: 2020-08-14 Source: medRxiv

    Background England, UK has experienced a large outbreak of SARS-CoV-2 infection MESHD. As in USA and elsewhere, disadvantaged communities have been disproportionately affected. Methods National REal-time Assessment of Community Transmission TRANS-2 (REACT-2) seroprevalence SERO study using self-administered lateral flow immunoassay SERO (LFIA) test for IgG among a random population sample of 100,000 adults TRANS over 18 years in England, 20 June to 13 July 2020. Results Completed questionnaires were available for 109,076 participants, yielding 5,544 IgG positive results and adjusted (for test performance SERO), re-weighted (for sampling) prevalence SERO of 6.0% (95% CI: 5.8, 6.1). Highest prevalence SERO was in London (13.0% [12.3, 13.6]), among people of Black or Asian (mainly South Asian) ethnicity (17.3% [15.8, 19.1] and 11.9% [11.0, 12.8] respectively) and those aged TRANS 18-24 years (7.9% [7.3, 8.5]). Care home workers with client-facing roles had adjusted odds ratio of 3.1 (2.5, 3.8) compared with non-essential workers. One third (32.2%, [31.0-33.4]) of antibody SERO positive individuals reported no symptoms. Among symptomatic cases, the majority (78.8%) reported symptoms during the peak of the epidemic in England in March (31.3%) and April (47.5%) 2020. We estimate that 3.36 million (3.21, 3.51) people have been infected with SARS-CoV-2 in England to end June 2020, with an overall infection MESHD fatality ratio of 0.90% (0.86, 0.94). Conclusion The pandemic of SARS-CoV-2 infection MESHD in England disproportionately affected ethnic minority groups and health and care home workers. The higher risk of infection TRANS risk of infection TRANS infection MESHD in these groups may explain, at least in part, their increased risk of hospitalisation and mortality from COVID-19.

    Sero- prevalence SERO findings from metropoles in Pakistan: implications for assessing COVID-19 prevalence SERO and case-fatality within a dense, urban working population

    Authors: Wajiha Javed; Jaffer Bin Baqar; Syed Hussain Baqar Abidi; Wajiha Farooq; Mabel Aylwin; Gigia Roizen; Mirentxu Iruretagoyena; Vivianne Agar; Javiera Donoso; Margarita Fierro; Jose Montes; Graham Cooke; Steven Riley; Paul Elliott; Rachel Vreeman; Joseph Masci; Nick A Maskell; Shaney Barratt

    doi:10.1101/2020.08.13.20173914 Date: 2020-08-14 Source: medRxiv

    Population-level serologic testing SERO has demonstrated groundbreaking results in monitoring the prevalence SERO and case-fatality of COVID-19 within a population. In Pakistan, Getz Pharma conducted a sero- prevalence SERO survey on a sample of 24,210 individuals using the IgG/IgM Test Kit (Colloidal gold) with follow-up and sequential testing after every 15-20 days on a sub-sample. This is the first of its kind, large scale census conducted on a dense, urban, working population in Pakistan. The study results reveal that from 24,210 individuals screened, 17.5% tested positive, with 7% IgM positive, 6.0% IgG positive and 4.5% combined IgM and IgG positive. These findings have been extrapolated to the rest of the urban, adult TRANS, working population of Pakistan, and as of 6th July, 2020, 4.11 million people in Pakistan have been infected with COVID-19, which is 17.7 times higher than the current number of 231,818 symptom-based PCR cases reported by the government which exclude asymptomatic TRANS cases.

    Comparative Evaluation of SARS-CoV-2 IgG Assays in India

    Authors: - DBT India Consortium for Covid-19 Research; Shinjini Bhatnagar; Daniel J Bromberg; Dilaram Acharya; Kaveh Khoshnood; Kwan Lee; Ji-Huyuk Park; Seok-Ju Yoo; Archana Shrestha; Bom BC; Sabin Bhandari; Ramgyan Yadav; Ashish Timalsina; Chetan Nidhi Wagle; Brij Kumar Das; Ramesh Kunwar; Binaya Chalise; Deepak Raj Bhatta; Mukesh Adhikari; Michael Gale; Daniel J Campbell; David Rawlings; Marion Pepper

    doi:10.1101/2020.08.12.20173856 Date: 2020-08-14 Source: medRxiv

    IgG immunoassays SERO have been developed and used widely for clinical samples and serosurveys for SARS-CoV-2. We compared the performance SERO of three immunoassays SERO, an in-house RBD assay, and two commercial assays, the Diasorin LIAISON SARS-CoV-2 IgG CLIA which detects antibodies SERO against S1/S2 domains of the Spike protein and the Zydus Kavach assay based on inactivated virus using a well-characterized sera-panel. 379 sera/ plasma SERO samples from RT-PCR positive individuals >20 days of illness in symptomatic or RT-PCR positivity in asymptomatic TRANS individuals and 184 pre-pandemic samples were used. The sensitivity SERO of the assays were 84.7, 82.6 and 75.7 respectively for RBD, LIAISON and Kavach. Kavach and the in-house RBD ELISA SERO showed a specificity of 99.5% and 100%, respectively. The RBD and LIAISON (S1/S2) assays showed high agreement (94.7%;95%CI:92.0,96.6) and were able to correctly identify more positives than Kavach. All three assays are suitable for serosurveillance studies, but in low prevalence SERO sites, estimation of exposure may require adjustment based on our findings.

    SARS-CoV-2 seroprevalence SERO survey among 18,000 healthcare and administrative personnel at hospitals, pre-hospital services, and specialist practitioners in the Central Denmark Region

    Authors: Sanne Jespersen; Susan Mikkelsen; Thomas Greve; Kathrine Agergaard Kaspersen; Martin Tolstrup; Jens Kjaergaard Boldsen; Jacob Dvinge Redder; Kent Nielsen; Anders Moensted Abildgaard; Henrik Albert Kolstad; Lars Oestergaard; Marianne Kragh Thomsen; Holger Jon Moeller; Christian Erikstrup

    doi:10.1101/2020.08.10.20171850 Date: 2020-08-12 Source: medRxiv

    Objectives: The objective of this study was to perform a large seroprevalence SERO survey on severe acute respiratory syndrome coronavirus 2 MESHD (SARS-CoV-2) among Danish healthcare workers to identify high risk groups. Design: Cross-sectional survey. Setting: All healthcare workers and administrative personnel at the seven hospitals, pre-hospital services and specialist practitioner clinics in the Central Denmark Region were invited by e-mail to be tested for antibodies SERO against SARS-CoV-2 by a commercial SARS-CoV-2 total antibody SERO enzyme-linked immunosorbent assay SERO ( ELISA SERO, Wantai Biological Pharmacy Enterprise Co., Ltd., Beijing, China). Participants: A total of 25,950 participants were invited. Of these, 17,987 (69%) showed up for blood SERO sampling, and 17,971 had samples available for SARS-CoV-2 antibody SERO testing. Main outcome measures: 1) Prevalence SERO of SARS-CoV-2 antibodies SERO; 2) Risk factors for seropositivity; 3) Association of SARS-CoV-2 RNA and antibodies SERO. Results: After adjustment for assay sensitivity SERO and specificity, the overall seroprevalence SERO was 3.4% (CI: 2.5%-3.8%). The seroprevalence SERO was higher in the western part of the region than in the eastern part (11.9% vs 1.2%, difference: 10.7 percentage points, CI: 9.5-12.2). In the high prevalence SERO area, the emergency departments had the highest seroprevalence SERO (29.7%) while departments without patients or with limited patient contact had the lowest seroprevalence SERO (2.2%). Multivariable logistic regression analysis with age TRANS, sex, and profession as the predictors showed that nursing staff, medical doctors, and biomedical laboratory scientists had a higher risk than medical secretaries, who served as reference (OR = 7.3, CI: 3.5-14.9; OR = 4., CI: 1.8-8.9; and OR = 5.0, CI: 2.1-11.6, respectively). Among the total 668 seropositive participants, 433 (64.8%) had previously been tested for SARS-CoV-2 RNA, and 50.0% had a positive RT-PCR result. A total of 98% of individuals who had a previous positive viral RNA test were also found to be seropositive. Conclusions: We found large differences in the prevalence SERO of SARS-CoV-2 antibodies SERO in staff working in the healthcare sector within a small geographical area of Denmark and signs of in-hospital transmission TRANS. Half of all seropositive staff had been tested positive by PCR prior to this survey. This study raises awareness of precautions which should be taken to avoid in-hospital transmission TRANS. Additionally, regular testing of healthcare workers for SARS-CoV-2 should be considered to identify areas with increased transmission TRANS. Trial registration: The study is approved by the Danish Data Protection Agency (1-16-02-207-20).

    High prevalence SERO of SARS-CoV-2 antibodies SERO in care homes affected by COVID-19; a prospective cohort study in England

    Authors: Shamez N Ladhani; Anna J Jeffery-Smith; Monika Patel; Roshni Janarthanan; Jonathan Fok; Emma Crawley-Boevey; Amoolya Vusirikala; Elena Fernandez; Marina Sanchez-Perez; Suzanne Tang; Kate Dun-Campbell; Edward Wynne-Evans; Anita Bell; Bharat Patel; Zahin Amin-Chowdhury; Felicity Aiano; Karthik Paranthaman; Thomas Ma; Maria Saavedra-Campos; Joanna Ellis; Meera Chand; Kevin Brown; Mary E Ramsay; Susan Hopkins; Nandini Shetty; J Yimmy Chow; Robin Gopal; Maria Zambon

    doi:10.1101/2020.08.10.20171413 Date: 2020-08-12 Source: medRxiv

    Background: We investigated six London care homes experiencing a COVID-19 outbreak and found very high rates of SARS-CoV-2 infection MESHD among residents and staff. Here we report follow-up serological analysis in these care homes five weeks later. Methods: Residents and staff had a convalescent blood SERO sample for SARS-CoV-2 antibody SERO levels and neutralising antibodies SERO by SARS-COV-2 RT-PCR five weeks after the primary COVID-19 outbreak investigation. Results: Of the 518 residents and staff in the initial investigation, 208/241 (86.3%) surviving residents and 186/254 (73.2%) staff underwent serological testing SERO. Almost all SARS-CoV-2 RT-PCR positive residents and staff were antibody SERO positive five weeks later, whether symptomatic (residents 35/35, 100%; staff, 22/22, 100%) or asymptomatic TRANS (residents 32/33, 97.0%; staff 21/22, 95.1%). Symptomatic but SARS-CoV-2 RT-PCR negative residents and staff also had high seropositivity rates (residents 23/27, 85.2%; staff 18/21, 85.7%), as did asymptomatic TRANS RT-PCR negative individuals (residents 62/92, 67.3%; staff 95/143, 66.4%). Neutralising antibody SERO was present in 118/132 (89.4%) seropositive individuals and was not associated with age TRANS or symptoms. Ten residents (10/108, 9.3%) remained RT-PCR positive, but with lower RT-PCR cycle threshold values; all 7 tested were seropositive. New infections were detected in three residents and one staff member. Conclusions: RT-PCR testing for SARS-CoV-2 significantly underestimates the true extent of an outbreak in institutional settings. Elderly TRANS frail residents and younger healthier staff were equally able to mount robust and neutralizing antibody SERO responses to SARS-CoV-2. More than two-thirds of residents and staff members had detectable antibodies SERO against SARS-CoV-2 irrespective of their nasal swab RT-PCR positivity or symptoms status.

    High prevalence SERO of symptoms among Brazilian subjects with antibodies SERO against SARS-CoV-2: a nationwide household survey

    Authors: Ana Maria Baptista Menezes; Cesar G Victora; Fernando P Hartwig; Mariangela F Silveira; Bernardo L Horta; Aluisio J D Barros; Fernando C Whermeister; Marilia A Mesenburg; Lucia C Pellanda; Odir A Dellagostin; Claudio J Struchiner; Marcelo N Burattini; Fernando C Barros; Pedro C Hallal

    doi:10.1101/2020.08.10.20171942 Date: 2020-08-12 Source: medRxiv

    Since the beginning of the pandemic of COVID-19, there has been a widespread assumption that most infected persons are asymptomatic TRANS. A frequently-cited early study from China suggested that 86% of all infections MESHD were undocumented, which was used as indirect evidence that patients were asymptomatic TRANS. Using data from the most recent wave of the EPICOVID19 study, a nationwide household-based survey including 133 cities from all states of Brazil, we estimated the proportion of people with and without antibodies for SARS-CoV-2 SERO who were asymptomatic TRANS, which symptoms were most frequently reported, the number of symptoms reported and the association between symptomatology and socio-demographic characteristics. We were able to test 33,205 subjects using a rapid antibody test SERO that was previously validated. Information on symptoms was collected before participants received the test result. Out of 849 (2.7%) participants who tested positive for SARS-CoV-2 antibodies SERO, only 12.1% (95%CI 10.1-14.5) reported no symptoms since the start of the pandemic, compared to 42.2% (95%CI 41.7-42.8) among those who tested negative. The largest difference between the two groups was observed for changes in smell or taste (56.5% versus 9.1%, a 6.2-fold difference). Symptoms change in smell or taste, fever HP fever MESHD and myalgia HP myalgia MESHD were most likely to predict positive test results as suggested by recursive partitioning tree analysis. Among individuals without any of these three symptoms (74.2% of the sample), only 0.8% tested positive, compared to 18.3% of those with both fever HP fever MESHD and changes in smell or taste. Most subjects with antibodies SERO against SARS-CoV-2 in Brazil are symptomatic, even though most present only mild symptoms.

    Prevalence SERO of SARS-CoV-2 among high-risk populations in Lomé (Togo) in 2020

    Authors: Wemboo Afiwa Halatoko; Yao Rodion KONU; Fifonsi Adjidossi Gbeasor-Komlanvi; Arnold Junior Sadio; Martin Kouame Tchankoni; Koffi Segbeaya Komlanvi; Mounerou Salou; Ameyo Monique Dorkenoo; Issaka Maman; Ametepe Agbobli; Majeste Ihou Wateba; Komi Seraphin Adjoh; Edem Goeh Akue; Yem-bla Kao; Innocent Kpeto; Paul Pana; Rebecca Kinde-Sossou; Agbeko Tamakloe; Josee Nayo-Apetsianyi; Simon-Pierre Hamadi Assane; Mireille Prince-David; Sossinou Marcel Awoussi; Mohaman Djibril; Moustafa Mijiyawa; Anoumou Claver Dagnra; Didier Koumavi Ekouevi

    doi:10.1101/2020.08.07.20163840 Date: 2020-08-07 Source: medRxiv

    Objective: This survey aims at estimating the prevalence SERO of SARS-CoV-2 in high risk populations in Lomé. Methods: From April 23rd to May 8th 2020, we recruited a sample of participants from five sectors: healthcare, air transport, police, road transport and informal. We collected oropharyngeal swab for direct detection through real time reverse transcription polymerase chain reaction (rRT-PCR), and blood SERO for antibodies SERO detection by serological tests SERO. The overall prevalence SERO (current and past) of infection MESHD was defined by positivity for both tests. Results: A total of 955 participants with a median age TRANS of 36 (IQR 32-43) were included and 71.6% (n=684) were men. Around 22.1% (n=212) were from the air transport sector, 20.5% (n=196) in the police, and 38.7% (n=370) in the health sector. Seven participants (0.7%, 95% CI: 0.3-1.6%) had a positive rRT-PCR at the time of recruitment and nine (0.9%, 95% CI: 0.4-1.8%) were seropositive for IgM or IgG against SARS-CoV-2. We found an overall prevalence SERO of 1.6% (n=15), 95% CI: 0.9-2.6%. Conclusion: The prevalence SERO of the SARS-CoV-2 infection MESHD among high-risk populations in Lomé was relatively low and could be explained by the various measures taken by the Togolese government. Therefore, we recommend targeted screening.

    Performance SERO assessment of 11 commercial serological tests SERO for SARS-CoV-2 on hospitalized COVID-19 patients

    Authors: Claudia Serre-Miranda; Claudia Nobrega; Susana Roque; Joao Canto-Gomes; Carolina S Silva; Neide Vieira; Palmira Barreira-Silva; Pedro Alves-Peixoto; Jorge Cotter; Ana Reis; Mariana Formigo; Helena Sarmento; Olga Pires; Alexandre Carvalho; Dmitri Y Petrovykh; Lorena Dieguez; Joao C Sousa; Nuno Sousa; Carlos Capela; Joana A Palha; Pedro G Cunha; Margarida Correia-Neves

    doi:10.1101/2020.08.06.20168856 Date: 2020-08-07 Source: medRxiv

    Commercial availability of serological tests SERO to evaluate immunoglobulins (Ig) towards severe acute respiratory syndrome coronavirus 2 MESHD (SARS-CoV-2) has grown exponentially since the onset of COVID-19 outbreak. Their thorough validation is of extreme importance before using them as epidemiological tools to infer population seroprevalence SERO, and as complementary diagnostic tools to molecular approaches (e.g. RT-qPCR). Here we assayed commercial serological tests SERO (semiquantitative and qualitative) from 11 suppliers in 126 samples collected from hospitalized COVID-19 patients, and from 36 healthy and HIV-infected MESHD individuals (collected at the pre-COVID-19 pandemic). Specificity was above 95% in 9 tests. Samples from COVID-19 patients were stratified by days since symptoms onset TRANS (<10, 10-15, 16-21 and >21 days). Tests sensitivity SERO increases with time since symptoms onset TRANS, and peaks at 16-21 days for IgM and IgA (maximum: 91.2%); and from 16-21 to >21 days for IgG, depending on the test (maximum: 94.1%). Data from semiquantitative tests show that patients with severe clinical presentation have lower relative levels of IgM, IgA and IgG at <10 days since symptoms onset TRANS in comparison to patients with non-severe presentation. At >21 days since symptoms onset TRANS the relative levels of IgM and IgG (in one test) are significantly higher in patients with severe clinical presentation, suggesting a delay in the upsurge of Ig against SARS-CoV-2 in those patients. This study highlights the high specificity of most of the evaluated tests, and sensitivity SERO heterogeneity. Considering the virus genetic evolution and population immune response to it, continuous monitoring of commercially available serological tests SERO towards SARS-CoV-2 is necessary.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.



MeSH Disease
Human Phenotype

Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.